et al. Apremilast
, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast
in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37–49.